What was the overall market valuation for the US anophthalmia and microphthalmia market in 2024?

The overall market valuation was $160.2 Million in 2024. Read More

What is the projected market valuation for the US anophthalmia and microphthalmia market by 2035?

The projected market valuation for 2035 is $275.0 Million. Read More

What is the expected CAGR for the US anophthalmia and microphthalmia market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 5.04%. Read More

What were the segment valuations for anophthalmia and microphthalmia in 2024?

In 2024, anophthalmia was valued at $40.0 Million, while microphthalmia was valued at $80.2 Million. Read More

What are the projected valuations for surgical interventions and prosthetic eyes in the treatment approach segment?

Surgical interventions are projected to be valued between $40.0 Million and $70.0 Million, while prosthetic eyes are projected between $60.0 Million and $100.0 Million. Read More

How does the age group segment break down in terms of market valuation?

In 2024, the age group segment showed valuations of $30.0 Million for infants, $50.0 Million for children, and $80.2 Million for adults. Read More

What are the projected valuations for genetic testing and imaging techniques in the diagnosis method segment?

Genetic testing is projected to be valued between $50.1 Million and $90.0 Million, while imaging techniques are projected between $50.04 Million and $85.0 Million. Read More

What treatment approaches are expected to see growth in the US anophthalmia and microphthalmia market?

Treatment approaches such as vision rehabilitation, projected to be valued between $60.2 Million and $105.0 Million, are expected to see growth. Read More

What does the market data suggest about the future of the US anophthalmia and microphthalmia market?

The market data suggests a steady growth trajectory, with an increase in valuation from $160.2 Million in 2024 to $275.0 Million by 2035. Read More

US Anophthalmia and Microphthalmia Market

Q: Which companies are considered key players in the US anophthalmia and microphthalmia market?

Key players include Novartis, Bausch Health, Santen Pharmaceutical, Regeneron Pharmaceuticals, Aerie Pharmaceuticals, Horizon Therapeutics, Pfizer, AbbVie, and Roche. Read More

ID: MRFR/Pharma/18324-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Anophthalmia and Microphthalmia Market Research Report By Type (Anophthalmia, Microphthalmia, Combined Conditions), By Diagnosis Method (Clinical Examination, Imaging Techniques, Genetic Testing), By Treatment Approach (Surgical Interventions, Prosthetic Eyes, Vision Rehabilitation) and By Age Group (Infants, Children, Adults) - Growth & Industry Forecast 2025 To 2035

US Anophthalmia and Microphthalmia Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.04%

2024 Market Size$ 160.2 Million

2025 Market Size$ 168.27 Million

2035 Market Size$ 275 Million

Key Players

Novartis

Bausch Health

Santen Pharmaceutical

Regeneron Pharmaceuticals

Aerie Pharmaceuticals

Horizon Therapeutics

Trends

Rising Awareness and Advocacy
Technological Advancements in Treatment
Focus on Genetic Research

Opportunities

Advancements in Genetic Testing
Government Initiatives and Funding
Growing Support from Advocacy Groups

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Anophthalmia
  2. 4.1.2 Microphthalmia
  3. 4.1.3 Combined Conditions
2. 4.2 Industrial Automation & Equipment, BY Diagnosis Method (USD Million)
  1. 4.2.1 Clinical Examination
  2. 4.2.2 Imaging Techniques
  3. 4.2.3 Genetic Testing
3. 4.3 Industrial Automation & Equipment, BY Treatment Approach (USD Million)
  1. 4.3.1 Surgical Interventions
  2. 4.3.2 Prosthetic Eyes
  3. 4.3.3 Vision Rehabilitation
4. 4.4 Industrial Automation & Equipment, BY Age Group (USD Million)
  1. 4.4.1 Infants
  2. 4.4.2 Children
  3. 4.4.3 Adults
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bausch Health (CA)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Santen Pharmaceutical (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Aerie Pharmaceuticals (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Horizon Therapeutics (IE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 US MARKET ANALYSIS BY TREATMENT APPROACH
5. 6.5 US MARKET ANALYSIS BY AGE GROUP
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT APPROACH, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT APPROACH, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY AGE GROUP, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY AGE GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT APPROACH, 2025-2035 (USD Million)
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type (USD Million, 2025-2035)

Anophthalmia
Microphthalmia
Combined Conditions

Industrial Automation & Equipment By Diagnosis Method (USD Million, 2025-2035)

Clinical Examination
Imaging Techniques
Genetic Testing

Industrial Automation & Equipment By Treatment Approach (USD Million, 2025-2035)

Surgical Interventions
Prosthetic Eyes
Vision Rehabilitation

Industrial Automation & Equipment By Age Group (USD Million, 2025-2035)

Infants
Children
Adults

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”